1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. News
  7. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
Delayed Nasdaq  -  04:00 2022-08-17 pm EDT
39.37 USD   -8.19%
08/17Novavax's COVID-19 Vaccine Gets Expanded Provisional Approval as Booster in New Zealand
MT
08/17Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as a First and Second Booster for Adults
PR
08/16Novavax Files in Taiwan for Expanded Emergency Use Authorization of Nuvaxovid COVID-19 Vaccine in Adolescents Aged 12 Through 17
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Taiwan to receive first doses of Novavax COVID vaccine this week

06/29/2022 | 03:04am EDT
FILE PHOTO: Illustration shows vials labelled

TAIPEI (Reuters) - Taiwan will take delivery of its first doses of the Novavax Inc COVID-19 vaccine this week, received under the COVAX sharing scheme, the government said on Wednesday.

Taiwan's Central Epidemic Command Centre said the 504,000 doses would arrive on Thursday at Taipei's main international airport.

Taiwan is scheduled to receive 2.268 million doses of the Novavax vaccine in batches this year through the COVAX mechanism, it added.

The shot is yet to be authorised in the United States, but is cleared for use in adults in more than 40 countries including Canada, Australia and New Zealand.

The company's COVID-19 vaccine has been shown to be more than 90% effective in two large, late-stage trials.

Taiwan has to date been using the AstraZeneca PLC, Moderna Inc, BioNTech SE/Pfizer Inc and domestically developed Medigen vaccines.

Taiwan has a well-vaccinated population with more than 70% of its people having had a first booster shot, with second boosters now being rolled out.

The island of 23 million people has reported more than 3.7 million infections so far this year having previously kept the pandemic well under control, though new cases are now waning.

(Reporting by Ben Blanchard; Editing by Stephen Coates)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.38% 10962 Delayed Quote.26.78%
BIONTECH SE -5.19% 152.04 Delayed Quote.-41.02%
MODERNA, INC. -5.93% 158 Delayed Quote.-37.79%
MSCI TAIWAN (STRD) 0.41% 576.187 Real-time Quote.-22.75%
NOVAVAX, INC. -8.19% 39.37 Delayed Quote.-72.48%
All news about NOVAVAX, INC.
08/17Novavax's COVID-19 Vaccine Gets Expanded Provisional Approval as Booster in New Zealand
MT
08/17Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New ..
PR
08/16Novavax Files in Taiwan for Expanded Emergency Use Authorization of Nuvaxovid COVID-19 ..
AQ
08/16Novavax Submits COVID-19 Booster Jab For US FDA's Approval
MT
08/15Novavax Seeks Emergency Use Authorization From FDA for COVID-19 Vaccine as Booster for ..
MT
08/15Novavax seeks U.S. authorization for COVID vaccine booster
RE
08/15Novavax seeks U.S. authorization for COVID vaccine booster
RE
08/15Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax..
PR
08/15Novavax, Inc. Submits Application to the U.S. FDA for Emergency Use Authorization for N..
CI
08/15Novavax and partner SK bioscience will provide the first protein-based COVID-19 vaccine..
AQ
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Financials (USD)
Sales 2022 2 379 M - -
Net income 2022 319 M - -
Net cash 2022 2 508 M - -
P/E ratio 2022 9,97x
Yield 2022 -
Capitalization 3 079 M 3 079 M -
EV / Sales 2022 0,24x
EV / Sales 2023 -0,09x
Nbr of Employees 1 541
Free-Float 98,8%
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 39,37 $
Average target price 125,83 $
Spread / Average Target 220%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.-72.48%3 079
MODERNA, INC.-37.79%65 706
IQVIA HOLDINGS INC.-13.27%45 640
LONZA GROUP AG-26.68%43 587
SEAGEN INC.10.47%31 450
ALNYLAM PHARMACEUTICALS, INC.31.58%27 384